Luliconazole is a wide spectrum antifungal agent and is very potent against dermatophytes with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has been found to be more potent than its racemic mixture, Lanoconazole.  A simple, accurate, specific, precise, robust, rapid and selective stability indicating high performance liquid chromatography (HPLC) method was developed for the assay of Luliconazole in bulk and gel based formulation. The HPLC separation was achieved on kromasil C18 (100mm × 4.6mm, 5 μm) column using a mobile phase of ACN: water (70:30, v/v) adjusted the pH 3 with 0.1% orthophosphoric acid at a flow rate of 1 mL· min^-1and UV detection at 295 nm. Peak elutes at 6.15 min appropriate. The method was validated for linearity, repeatability, accuracy, precision, robustness, limit of detection and limit of quantification. The accuracy was between 99.2 -99.6%. The highest R.S.D. amongst interday and intraday precision were found to be 0.24 and 0.17 respectively. The assay was linear over the concentration range of 10-50 μg/ml (R²≈0.999). LOD and LOQ were found to be 0.099 and 0.3005 respectively. Stress testing was carried out in presence of acid, base, hydrogen peroxide, heat and light to demonstrate speci?city of the method as per ICH guidelines. The developed method could separate the potential degradation products from the Luliconazole peak. It was concluded that highest degradation occurred in basic condition. This proposed method was suitable and practical for analyzing the content of Luliconazole in pharmaceutical products and could be of bene?t for the prediction shelf life of Luliconazole in gel based formulations.

1. Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole.Med Mycol. 2009February;47(6):640-7.doi:10.1080/13693780802541518, PMID 19115136.
2. Jarratt M, Jones T, Kempers S, Rich P, Morton K, Nakamura N, Tavakkol A. Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.Cutis.2013March;91(4):203-10. PMID 23763082.
3. Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Mumbai: Universal Publishing Corporation; 1999. p.119-23. Available link: https://apps.who.int/iris/handle/10665/42188
4. Sonawane S. Application of experimental design for the optimization of forced degradation and development of validated stability indicating HPLC method for luliconazole in bulk and cream formulation. ArabJ Chem. 2016February;2:1429-34. doi: 10.1016/j.arabjc.2012.03.019
5. Malaysiya A. Method Development and Validation of RPHPLC Method for Assay and related substances of luliconazole in Topical Dosage form.Int J Pharm ChemAnal. 2017April2;4(2):46-50. doi: 10.18231/2394-2797.2017.0012
6. SRTambe SS, Bhonsle AP. Estimation of Luliconazole in Formulation and Biofluid. J Anal Pharm Res. 2017;6(5):00187. Doi: 10.15406/japlr.2017.06.00187
7. Malasiya A, Goyal A. Method Development and Validation of RPHPLC Method for Assay and related Substances of luliconazole in Topical Dosage form. Int J Pharm ChemAnal.2017February;4(2):46-50. Doi: 10.18231/2394-2797.2017.0012
8. Gummadi S, Kommoju M. Quantification and stability aspects of luliconazole in bulk and pharmaceutical dosage forms by UV spectroscopy. J Drug Deliv Ther. 2019March9; 2:48-52. doi: 10.22270/jddt.v9i2-s.2715  
9. Tomal M, Hasan R, Pramanik R. Method development and validation of RP-HPLC method for estimation of luliconazole in marketed formulation (Cream). J PharmInnov. 2019May8(5):103-108. Available from: https://www.thepharmajournal.com/archives/2019/vol8issue5/PartB/8-2-149-480.pdf
10. Malasiya A, Goyal A. Method Development and Validation of RPHPLC Method for Assay and related Substances of luliconazole in Topical Dosage form. Int J Pharm Chem Anal. 2020February;4(2):46-50. doi: 10.18231/2394-2797.2017.0012
11. R Tambe S, Sd S, P Bhosale A. Estimation of Luliconazole in Formulation and Biofluid. JAPLR;6(5). doi: 10.15406/japlr.2017.06.00187.
12. Chaudhari MJ, Chaudhari SR, Chalikwar SC, ShirkhedkarAA. Application of area under curve technique for UV-spectrophotometric determination of luliconazole in bulk and pharmaceutical formulation. Asian. J Pharm Ana. 2018October; 8(1):45-8. Doi: 10.5958/2231-5675.2018.00008.X
13. ICH, Q1A (R2) Stability testing of new drug substances and products, International Conference on Harmonization, 2003. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf
14. International conference on harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use, Validation of analytical procedures: Text methodology, (Q2 (R1) Geneva; 2005. p. 6-13.
15. Draft guidance analytical procedures and method validation, US Food and Drug Administration, Centre for drugs and biologics. Department of Health and Human Services; 2000 [cited on 11/8/2020]. Available from: http://www.fda.gov/cder/guidance/2396dft.htm#111.
16. ICH Q. Validation of analytical procedures (definitions and terminology). 2005; R1:9-10.
17. Malasiya Aditi, GoyalAditi. Method Development and Validation of RP HPLC Method for Assay and related Substances of  Luliconazole in Topical Dosage form. IJPCA 2017; 4(2): 46-50. Doi: 10.18231/2394-2797.2017.0012
18. Desai NJ, Maheshwari DG. UV Spectrophotometric Method for the Estimation of Luliconazole in Marketed Formulation (Lotion). IJPSR 2014; 5(2): 48-54. Available from: http://www.pharmasm.com/pdf_files/20140714204706_06_noopur.pdf